title: Intravenous zoledronate for osteoporosis: less might be more.
abstract: Annual administration of 5 mg intravenous zoledronate is moderately effective in reducing fracture risk in older adults, decreasing the relative risk of clinical fracture by 33%. However, almost 10 years after its approval for use in clinical practice there remain very substantial uncertainties about the optimal treatment regimen, that is, the lowest dose and/or longest dosing interval that is efficacious. Several pieces of clinical research suggest that the current recommendation for annual administration of 5 mg zoledronate might represent overtreatment. Clinical trials to clarify the optimal use of zoledronate for reduction of fracture risk should be undertaken.
authors: Department of Medicine, University of Auckland, Private Bag 92109, Auckland, New Zealand.
authors: Andrew
authors: A
authors: Grey
keywords: dosage; duration; fracture risk; intravenous; osteoporosis; zolendronate